The first and only once-monthly treatment targeting factor XIIa to prevent recurrent attacks of hereditary angioedema \(HAE\) has been authorized by Health Canada. This marks the seventh approval of this innovative therapy worldwide, reflecting CSL’s decades-long commitment to delivering innovative treatments to offer those living with HAE a convenient administration method for long-term control over their disease. Learn more: https://bit.ly/46MYCtN
CSL's 2025 Full Year Financial Results
CSL will announce its Full Year Financial Results for the period ending 30th June 2025 on Tuesday, 19th August 2025.
Webcast will be live from 10:00am (AEST) on announcement day.
CSL's 2025 Half Year Financial Results Click here for Full Information including Webcast Recording → | Would you like to read our 2024 Annual Report? Click here to view or download the Annual Report →
CSL. Always Evolving for a Better World.
CSL has delivered biotechnology excellence for over a century. Today, with the combined expertise of CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor, CSL’s offerings are more diverse than ever to help ensure patients and people everywhere get the treatments they need. We’re always improving so life can, too.
Our Businesses and Products
CSL. Always Evolving for a Better World.
CSL has delivered biotechnology excellence for over a century. Today, with the combined expertise of CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor, CSL’s offerings are more diverse than ever to help ensure patients and people everywhere get the treatments they need. We’re always improving so life can, too.
Our Businesses and Products
CSL Behring. Leading the Way in Treating Rare and Serious Diseases.
CSL Behring is a global biotech leader with a broad range of biotherapies for rare and serious diseases including bleeding disorders, immunodeficiencies, hereditary angioedema, neurological disorders and Alpha 1 Antitrypsin Deficiency.
More About CSL Behring
CSL Seqirus. Global Vaccine Leader.
Through the power of innovation, our vision is to advance science to enhance public health worldwide. We stand on the front line with partners in public health discovering, developing, and delivering pioneering vaccine solutions to safeguard people and communities across the world.
More About CSL Seqirus
CSL Vifor. Changing the Game in Iron Deficiency and Nephrology.
The newest member of the CSL family, CSL Vifor is a global leader in iron deficiency and nephrology and is committed to launching the next generation of therapies to truly address the full spectrum of kidney disease, with a focus on dialysis and rare disease.
More About CSL ViforVita: Original Stories
'Vita' means life. It's also where we share the stories of biotech's promise to patients and public health.
Careers at CSL
We are committed to helping employees fulfill their career aspirations while working in a values-based culture. Are you next?
Pictured: A CSL employee in Bern, Switzerland
8 Aug
7 Aug
Meet the 2025 CSL Community Impact Award winners! We’re proud to support these incredible organisations making a lasting difference across Australia, from allergy care and heart health to sport inclusion and food insecurity. Together, we’re helping expand their reach and deepen their impact for patients and communities across Australia. Click the link to learn more: https://lnkd.in/e5NGyG5c #CSL #CommunityImpactAwards
6 Aug
For more than a century, CSL has advanced public health through trusted science and innovative therapies. #CSL #PublicHealth #InnovationForLife See our impact: https://bit.ly/4lcO6zq
29 Jul
🎉 Take a look inside our award-winning #CSLBehring plasma base fractionation facility at Broadmeadows in Victoria, Australia! 🌏 Broadmeadows was recently named 2025 Facility of the Year in the category of Pharma 4.0 by the International Society for Pharmaceutical Engineering (ISPE ). The manufacturing site was honored for its “full-scale” use of robotics and automation technologies. Learn more about the Australian manufacturing site, which turns human plasma into critical medicines: https://bit.ly/3GLhDlO #CSL #Australia #ISPE #Engineering #Manufacturing #Broadmeadows
24 Jul
At CSL, support goes beyond the workplace. We’re proud to invest in the futures of our employees and their loved ones through the Promising Futures Scholarship Program. This initiative helps employees and their dependents—especially those overcoming barriers—pursue higher education and unlock new opportunities. Because when we support our people and their families, we build stronger communities and a brighter future for all. Ready to grow your career with a company that supports your whole family? https://bit.ly/3GIfhUJ #CSL #CSLCareers #PromisingFutures #LifeAtCSL
22 Jul
CSL partners with advocacy groups to support and empower people with rare and serious conditions, because care means more than medicine. #CSL #PatientFocus #RareDiseaseAdvocacy Learn more: https://bit.ly/40wY6Mu
21 Jul
On Sunday 13 July, more than 600 CSL colleagues took to the start line at Run Melbourne, conquering the half marathon, 10km and 5.5km events. They braved Melbourne’s winter chill and were rewarded with blue skies, epic vibes, and a powerful sense of camaraderie. We believe such spirit deserves its own collective noun: a promise of CSL Runners ❤️🏃 #RunMelbourne #CSLPromise #TeamCSL #CorporateWellbeing #MelbourneMoments
17 Jul
Making clinical trials more bear-able! 🐻 Check out why CSL decided to be the first ever to provide these innovative teddy bears to young participants in a clinical trial for hereditary angioedema. https://bit.ly/4kFSqa3 #CSL
16 Jul
Coming in May 2026: CSL Behring’s Gettin' In the Game Junior National Championship for kids and teens who have bleeding disorders Learn more about this fun and friendly sports competition! https://bit.ly/4lFoDjm
12 Jul
This NAIDOC Week, we honour the 2025 theme "The Next Generation: Strength, Vision & Legacy". Some of our activities and celebrations have included: Belle Hart, a proud Aboriginal woman, pharmacist and Victorian Program Coordinator for the Australian Alliance for Indigenous Genomics \@ WEHI, came and spoke to us about inclusive genomics and the importance of co-design in research. At our Broadmeadows manufacturing site, two walking paths were named in Woi Wurrung language with permission from the Wurundjeri Woi Wurrung Cultural Heritage Aboriginal Corporation. • barrawarn djinang – Magpies Footpath • wurun yana – Manna Gum Walk Many CSL employees have marked the week by attending local events, celebrations and educational sessions. Some visited the phenomenal “65,000 Years: A Short History of Australian Art” exhibition at the \@Potter Museum of Art, \@University of Melbourne – we highly recommend it. CSL remains committed to reconciliation and learning from, listening to and celebrating First Nations peoples, whose cultures, histories and contributions continue to enrich our communities and shape our shared future.